Shirish M. Gadgeel

Henry Ford Health System — United States

Medicine · Health Sciences

76h-index41.4kcitations843works5.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(455), Lung Cancer Research Studies(190), Colorectal Cancer Treatments and Studies(139), Lung Cancer Diagnosis and Treatment(129), Cancer Genomics and Diagnostics(129)

Publications837 total

Table S5 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025Open Access
Table S6 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025Open Access
Figure S4 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025Open Access
Supplementary Methods from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025Open Access
Figure S1 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025Open Access
Table S7 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025Open Access
Table S4 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025Open Access
Supplementary Figures S1-S16 from NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
2025Open Access
Table S2 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025Open Access
Table S8 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025Open Access
Figure S2 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025Open Access
Table S1 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025Open Access
Table S3 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025Open Access
Table S9 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025Open Access
Figure S7 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025Open Access
Figure S5 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025Open Access
Figure S6 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025Open Access
Figure S3 from SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
2025Open Access
Supplementary Data from Daclatasvir, an Antiviral Drug, Downregulates Tribbles 2 Pseudokinase and Resensitizes Enzalutamide-Resistant Prostate Cancer Cells
2025Open Access
Supplementary Table S3 from Assessing a Polygenic Risk Score for Lung Cancer Susceptibility in Non-Hispanic White and Black Populations
2025Open Access
page 1 of 42Next →

Frequent Co-authors

D. Ross Camidge(15), Enriqueta Felip(10), Alice T. Shaw(9), Sai‐Hong Ignatius Ou(9), Steven Powell(8), Lecia V. Sequist(8), Gregory J. Riely(8), Leena Gandhi(6), Edward B. Garon(6), James Chih‐Hsin Yang(6), Delvys Rodríguez‐Abreu(5), Emilio Esteban(5), Manuel Dómine(5), Maximilian J. Hochmair(5), Helge Bischoff(5), Nir Peled(5), Michael Boyer(5), M. Catherine Pietanza(5), Marina Chiara Garassino(5), Filippo de Marinis(5)